Calculation and application of activity discriminants in lead optimization

被引:0
作者
Luo, Xincai [1 ]
Krumrine, Jennifer R. [1 ]
Shenvi, Ashok B. [1 ]
Pierson, M. Edward [2 ]
Bernstein, Peter R. [1 ]
机构
[1] AstraZeneca, Dept Chem, Wilmington, DE 19850 USA
[2] AstraZeneca, Neurosci Therapeut Area, Wilmington, DE 19850 USA
关键词
In vitro activity; Linear discriminant analysis; Activity discriminant; Medicinal chemistry descriptors; Lead optimization; QSAR; POLAR SURFACE-AREA; DRUG DISCOVERY; QUANTITATIVE STRUCTURE; PHARMACOPHORE FINGERPRINTS; INDEPENDENT DESCRIPTORS; ADME EVALUATION; ATOM-TYPE; PREDICTION; QSAR; SOLUBILITY;
D O I
10.1016/j.jmgm.2010.07.005
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
We present a technique for computing activity discriminants of in vitro (pharmacological, DMPK, and safety) assays and the application to the prediction of in vitro activities of proposed synthetic targets during the lead optimization phase of drug discovery projects. This technique emulates how medicinal chemists perform SAR analysis and activity prediction. The activity discriminants that are functions of 6 commonly used medicinal chemistry descriptors can be interpreted easily by medicinal chemists. Further, visualization with Spotfire allows medicinal chemists to analyze how the query molecule is related to compounds tested previously, and to evaluate easily the relevance of the activity discriminants to the activities of the query molecule. Validation with all compounds synthesized and tested in AstraZeneca Wilmington since 2006 demonstrates that this approach is useful for prioritizing new synthetic targets for synthesis. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:372 / 381
页数:10
相关论文
共 69 条
[1]   Application of a Dried-DMSO rapid throughput 24-h equilibrium solubility in advancing discovery candidates [J].
Alelyunas, Yun W. ;
Liu, Ruifeng ;
Pelosi-Kilby, Luciana ;
Shen, Cindy .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2009, 37 (02) :172-182
[2]  
[Anonymous], COMPRENHENSIVE MED C
[3]  
[Anonymous], MOL DRUG PROPERTIES
[4]  
[Anonymous], 2004, DRUG DISCOVERY TODAY, DOI [10.1016/S1741-8364(04)02393-5, DOI 10.1016/S1741-8364(04)02393-5]
[5]   Combining pharmacophore fingerprints and PLS-discriminant analysis for virtual screening and SAR elucidation [J].
Askjaer, Sune ;
Langgard, Morten .
JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2008, 48 (03) :476-488
[6]  
Bhavani S, 2006, J CHEM INF MODEL, V46, P2478, DOI 10.1021/ci0601281
[7]   Fuzzy tricentric pharmacophore fingerprints.: 2.: application of topological fuzzy pharmacophore triplets in quantitative structure-activity relationships [J].
Bonachera, Fanny ;
Horvath, Dragos .
JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2008, 48 (02) :409-425
[8]  
Bridgland-Taylor M. H., 2006, Journal of Pharmacological and Toxicological Methods, V54, P189, DOI 10.1016/j.vascn.2006.02.003
[9]   Contemporary QSAR classifiers compared [J].
Bruce, Craig L. ;
Melville, James L. ;
Pickett, Stephen D. ;
Hirst, Jonathan D. .
JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2007, 47 (01) :219-227
[10]   ATOM PAIRS AS MOLECULAR-FEATURES IN STRUCTURE ACTIVITY STUDIES - DEFINITION AND APPLICATIONS [J].
CARHART, RE ;
SMITH, DH ;
VENKATARAGHAVAN, R .
JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES, 1985, 25 (02) :64-73